Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27978528 | 0.84 | — | — | |
| SCHEMBL9164824 | 0.80 | FDPS (0.39) | FAAHCA2MAPTTP53DNM1 | |
| SCHEMBL18008605 | 0.78 | TP53 (0.43) | FAAHCA2MAPTTP53TSHR | |
| SCHEMBL28234303 | 0.78 | CA2 (0.48) | CA2TP53CA1 | |
| Ammonia Solution, Strong SCHEMBL19811135 | 0.76 | TP53 (0.42) | FAAHCA2MAPTTP53TSHR | |
| SCHEMBL3722966 | 0.76 | EPHX1 (0.35) | FAAHCA2MAPTTP53DNM1 | |
| Potassium Ion SCHEMBL19811679 | 0.76 | FDFT1 (0.35) | FAAHCA2MAPTTP53TSHR | |
| Lithium Ion SCHEMBL19811155 | 0.76 | CA2 (0.34) | FAAHCA2MAPTTP53TSHR | |
| SCHEMBL19811115 | 0.76 | CA2 (0.38) | FAAHCA2MAPTTP53TSHR | |
| SCHEMBL27344552 | 0.76 | CA2 (0.34) | FAAHCA2MAPTTP53DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178411-A1 | Sulfonimide containing compounds and their use in polymer electrolyte membranes for electrochemical cells | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-08-10 | — | — | US | claimed |
| WO-2005003081-A2 | SULFONIMIDE CONTAINING COMPOUNDS AND THEIR USE IN POLYMER ELECTROLYTE MEMBRANES FOR ELECTROCHEMICAL CELLS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-01-13 | — | — | WO | claimed |
| EP-2714655-B1 | ALLYL ETHER-TERMINATED FLUOROALKANESULFINIC ACIDS, SALTS THEREOF, AND A METHOD OF MAKING THE SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9199929-B2 | Allyl ether-terminated fluoroalkanesulfinic acids, salts thereof, and a method of making the same | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140088322-A1 | ALLYL ETHER-TERMINATED FLUOROALKANESULFINIC ACIDS, SALTS THEREOF, AND A METHOD OF MAKING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012166578-A2 | ALLYL ETHER-TERMINATED FLUOROALKYL SULFINIC ACIDS AND SALTS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-06 | — | — | WO | disclosed |
| CN-101553465-B | Method for producing tris(perfluoroalkanesulfonyl)methide acid salt | CENTRAL GLASS CO LTD | 2012-07-18 | — | — | CN | disclosed |
| CN-101553465-A | Method for producing tris(perfluoroalkanesulfonyl)methide acid salt | CENTRAL GLASS CO LTD (JP) | 2009-10-07 | — | — | CN | disclosed |
| US-20060178411-A1 | Sulfonimide containing compounds and their use in polymer electrolyte membranes for electrochemical cells | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-08-10 | — | — | US | disclosed |
| WO-2005003081-A2 | SULFONIMIDE CONTAINING COMPOUNDS AND THEIR USE IN POLYMER ELECTROLYTE MEMBRANES FOR ELECTROCHEMICAL CELLS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178411-A1 | Sulfonimide containing compounds and their use in polymer electrolyte membranes for electrochemical cells | HCN2, KCNN2, NHERF1 | FAAH 3941/4885CA2 12/4885MAPT 4219/4885 |
| US-20140088322-A1 | ALLYL ETHER-TERMINATED FLUOROALKANESULFINIC ACIDS, SALTS THEREOF, AND A METHOD OF MAKING THE SAME | TST, PFAS, ALAD | FAAH 279/4885CA2 3208/4885MAPT 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.